These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18442506)

  • 1. The challenge of treating obesity: the endocannabinoid system as a potential target.
    Isoldi KK; Aronne LJ
    J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The endocannabinoid system].
    Sudano I; Périat D; Noll G
    Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoid control of food intake and energy balance.
    Di Marzo V; Matias I
    Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
    Sulcová A
    Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
    Patti ME
    J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors.
    Samaha FF; Chou CM
    Obesity (Silver Spring); 2009 Feb; 17(2):220-5. PubMed ID: 19039319
    [No Abstract]   [Full Text] [Related]  

  • 13. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
    Deedwania P
    Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
    Woods SC
    JAAPA; 2007 Nov; Suppl Endocannabinoid():7-10. PubMed ID: 18047036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
    Bramlage P; Böcking W; Kirch W
    Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.
    Bennetzen MF
    Dan Med Bull; 2011 Apr; 58(4):B4269. PubMed ID: 21466769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment.
    André A; Gonthier MP
    Int J Biochem Cell Biol; 2010 Nov; 42(11):1788-801. PubMed ID: 20541029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.